BioSphere Medical Names Joel B. Weinstein Vice President of Global Marketing and...

BioSphere Medical Names Joel B. Weinstein Vice President of Global Marketing and Sales

ROCKLAND, Mass.--(Business Wire)--BioSphere Medical, Inc. (NASDAQ: BSMD) ("BioSphere"), a medical
device company that has pioneered the use of bioengineered
microspheres to treat uterine fibroids, hypervascularized tumors, and
vascular malformations by a minimally invasive, image-guided medical
procedure called embolotherapy, today announced that Joel B. Weinstein
has been named to the newly created position of Vice President of
Global Marketing and Sales. Mr. Weinstein brings more than 20 years of
experience in the imaging and women's health industries to BioSphere.
He will report to Richard Faleschini, BioSphere's President and Chief
Executive Officer.

Weinstein spent 11 years as Vice President, Marketing and Business
Development of Hologic, Inc., one of the world's largest medical
device companies focused on women's health. He joined Hologic at its
inception, and during his tenure developed and executed strategies
that led to the company generating annual sales of more than $100
million. In addition to his global functional responsibilities, he
also assisted the company in raising its initial round of venture
capital financing and executing its IPO and secondary offering. Prior
to Hologic, Weinstein had progressively greater management
responsibilities over a seven year period with Advanced Technology
Laboratories (ATL), one of the world's leading multi-modality
diagnostic ultrasound companies. Along with several of its other major
product lines, ATL was a market share leader in hospital- and
office-based ultrasound systems marketed directly to obstetricians and
gynecologists.

Following Hologic and before joining BioSphere Medical, Mr.
Weinstein founded and led several medical device companies, and
founded his own firm, which provided strategic counsel to medical
device companies and venture capital firms.

Mr. Weinstein is a former Director of the Massachusetts Medical
Device Council (MassMEDIC), and a former member of the MassMEDIC FDA
Working Group and Reimbursement Working Group. He received his
bachelor's degree in Electrical Engineering from City College of New
York and an MBA from Western New England College.

Richard Faleschini, President and Chief Executive Officer of
BioSphere Medical, commented, "We welcome Joel to our Company and
expect he will significantly strengthen our management team. He brings
a unique combination of corporate experience and entrepreneurial
drive, as well as a proven track record of bringing new products to
the market, creating and cultivating global distribution channels, and
developing successful regulatory and reimbursement strategies. He will
play an important role in leveraging our leadership position in
interventional gynecology and oncology, and in particular we believe
he will advance our goal to re-accelerate UFE growth in the U.S. In
addition, he will direct our U.S. sales organization, which is on
track to increase by nearly a third in this current quarter."

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in
Rockland, Massachusetts, seeks to develop and commercialize minimally
invasive diagnostic and therapeutic applications based upon its
pioneering proprietary bioengineered microsphere technology. The
Company's core technologies, patented bioengineered polymers and
manufacturing methods, are used to produce microscopic spherical
materials with unique beneficial properties that are designed for a
variety of medical applications. BioSphere's principal focus is the
treatment of symptomatic uterine fibroids using a procedure called
uterine fibroid embolization, or UFE. The Company's products continue
to gain acceptance in this rapidly emerging procedure as well as in a
number of other new and established medical treatments.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. For a
discussion of important risks and uncertainties which could cause
actual results to differ from those contained in such forward-looking
statements, see "Risk Factors" in BioSphere's Quarterly Report on Form
10-Q for the quarter ended September 30, 2007, as filed by the Company
with the Securities and Exchange Commission, and described in other
filings made by the Company from time to time with the Securities and
Exchange Commission. The forward-looking statements in this press
release are made as of the date of this press release and the Company
disclaims any obligation to update these forward-looking statements as
a result of changed events, circumstances or otherwise.

BioSphere Medical, Inc.
Martin Joyce, 781-681-7925
Executive Vice President and
Chief Financial Officer
or
Investor Relations:
The Equity Group Inc.
Devin Sullivan, 212-836-9608
Senior Vice President

Copyright Business Wire 2008